Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety, tolerability, and immunogenicity of V116 in children with sickle cell disease has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections
• Sickle Cell Disease

Drugs mentioned

• V114 (15-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2021-06-16